Purpose: Aortic stenosis (AS) is a disease process akin to atherosclerosis and has been linked to several risk factors for coronary artery disease (CAD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker secreted in the atherosclerotic plaque. We hypothesized a relationship between serum Lp-PLA2, plasma oxidized LDL (oxLDL) and AS, in contrast with CAD.
Results:
In healthy controls, Lp-PLA2 was 163±43 μg/L (men: 166±45 μg/L; women: 159±39 μg/L, non significant). Lp-PLA2 were significantly higher in patients than in controls (219.2±49.1 vs 163.0±43.0; p=0.01). Lp-PLA2 increased in AS-patients, and were not significantly different than CADpatients (217.3±44.5 vs. 220.4±51.9, respectively; NS). Moreover, Lp-PLA2 levels were similar in patients with single-vessel atherosclerosis (215.2±52.0) but significantly lower than in patients with three-vessel atherosclerosis (251.9±5.7 μg/L; p=0.03).
OxLDL levels were 42±13 U/L, which was within normal values. oxLDL values were 46±12 and 38±12 U/L for AS-patients and CAD-patients, respectively, (p<0.0001). Circulating oxLDL levels were not affected by gender, diabetes or hypertension but were significantly correlated with serum apoB, LDL-cholesterol, triglycerides and ApoA-I. We found no correlation between Lp-PLA2 and oxLDL. Patients on statin treatment had significantly lower plasma oxLDL levels than patients without any hypolipidemic treatment.
Conclusion:
We report for the first time that high serum levels of Lp-PLA2 were associated with severe AS. This could have practical implications because statins and renin-angiotensin-aldosteron system inhibitors seemed to be a promising treatments of AS.
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Results:
Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic, mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean blood pressure was 139 (20)/84 (11) mmHg and median heart rate was 61 bpm [Interquatile range (IQR)] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . Mean HDL cholesterol was 43 mg/dl (11), mean LDL cholesterol 124 mg/dl (39) and median triglycerides were 147 mg/dl IQR . Mean Cockcroft-Gault creatinine clearance was 87 ml/min and 11 pts (1.4%) had a severe chronic renal failure (lower than 30 ml/min). Mean left ventricular ejection fraction was 0.53 (0.13). 88.5% were on antiplatelet therapy, 75.2% on beta-blocker, 66% on statin therapy and 54.8% on ACE inhibitors or ARB.
A previous history of COPD was present in 3.5% of pts; 37% of them had a beta-blocker therapy. The cumulative seven-year total mortality rate was 17.9% in the whole sample (51.8% in pts with COPD and 16.7% in those without, p<0.001). Among COPD pts with beta-blocker therapy, the mortality rate was 30% while mortality reached 64.7% in COPD pts without betablocker (p=0.08).
After multivariate adjustment for age, diabetes, tobacco consumption (none, d40 pack-years, >40 pack-years), heart rate, left ventricular ejection fraction (>0.5; d 0.5 and >0.35; d0.35), duration of CAD, ankle-brachial index (>0.9; d0.9 and >0.6; d0.6), history of stroke, statin therapy and coronary revascularization, hazard ratio for all-cause death was 2.22 (95% CI [1.15; 4.26] p=0.016) in pts with COPD compared to those without. 
